share_log

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

Benzinga ·  Nov 20, 2023 12:37

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment